cdk9 inhibition with voruciclib for treating aml and r/r b-cell nhl
Published 11 months ago • 104 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
1:32
the potential clinical significance of cdk6 inhibitors in leukemia
-
6:20
zella 101: alvocidib for newly diagnosed aml
-
1:02
the challenge of treating bpdcn in a resource-limited setting
-
1:22
an overview of clinical trials investigating btk inhibitors and degraders in mcl
-
0:58
first-in-human trial of cln-978, a novel cd19 bispecific antibody, for the treatment of r/r b-nhl
-
5:18
update on imgn632: cd123 antibody-drug conjugate for r/r aml and bpdcn
-
2:55
a model including cd49d expression to predict outcomes in patients with cll treated with ibrutinib
-
5:36
cdr or hv region and framework region
-
9:37
ccvip demonstrates the braillenote apex, part 1
-
6:16
cyclins and cdks cell cycle regulation
-
3:10
novel aml treament approaches
-
1:42
aml: new targeted inhibitors as single agents?
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
0:42
the limited access to novel therapeutics for sickle cell disease in lmics
-
1:49
bringing precision medicine and mrd into clinical strategies
-
1:17
keynote-667: pembrolizumab plus copdac-28 for high-risk chl with slow early response to oepa
-
1:43
eradic trial: preliminary results of mrd-guided ibrutinib plus venetoclax vs fcr
-
1:11
genomic testing can help identify patient risk factors and guide clinical decision-making
-
2:38
pain management in scd: integrating medications and non-pharmacological interventions
-
3:08
hypomethylating agents in aml
-
4:01
mechanisms and prospects of a novel cdk9 inhibitor